Mounjaro and Zepbound are the same medication (tirzepatide, made by Eli Lilly). The only difference is FDA approval: Mounjaro for type 2 diabetes, Zepbound for weight loss. Cash-pay cost is similar (~$1,000–$1,200/mo for either).
If you're paying cash, compounded tirzepatide at $165/month through Luma Health is roughly 1/7th the cost of either brand — same active ingredient, FDA-recognized 503A compounding pathway.
Information based on publicly available FDA labels, Eli Lilly product information, and cash-pay pricing as of June 2026. Both Mounjaro and Zepbound are legitimate FDA-approved medications. Compounded tirzepatide is dispensed under the FDA 503A pathway from licensed compounding pharmacies. This article is informational and not medical advice.
The Core Fact: Same Active Ingredient
Both Mounjaro and Zepbound contain tirzepatide as the active ingredient. Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. The molecule, formulation, doses (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg), and pen delivery system are identical across both products.
If you're prescribed Mounjaro at 10mg weekly, it works exactly the same as Zepbound at 10mg weekly. The difference isn't pharmacological — it's regulatory and commercial.
Side-by-Side Comparison Table
| Factor | Mounjaro | Zepbound | Compounded Tirzepatide (Luma Health) |
|---|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly | Licensed 503A compounding pharmacy (VialsRX) |
| FDA approval | Type 2 diabetes (May 2022) | Chronic weight management (Nov 2023) | 503A compounding pathway |
| Cash price (monthly) | ~$1,000–$1,200/mo | ~$1,000–$1,200/mo | $165/mo flat |
| Annual cash cost | ~$12,000–$14,400/yr | ~$12,000–$14,400/yr | $1,980/yr flat |
| Insurance coverage probability | High (for diabetes diagnosis) | Variable (depends on employer plan) | N/A — cash-pay model bypasses insurance |
| Doses available | 2.5/5/7.5/10/12.5/15mg | 2.5/5/7.5/10/12.5/15mg | Same range, dosed by clinician |
Why Two Brand Names?
Pharmaceutical companies typically launch a separate brand for each FDA-approved indication. This isn't unique to tirzepatide — semaglutide follows the same dual-brand pattern (Ozempic for diabetes, Wegovy for weight loss).
Reasons for the dual-brand approach:
- Regulatory clarity: Each FDA approval is for a specific condition with its own clinical trial data. Distinct labels make insurance billing cleaner.
- Commercial positioning: Marketing diabetes treatment vs. weight loss to different audiences. Each brand has its own messaging, packaging, and patient education.
- Insurance dynamics: Diabetes drugs typically have higher insurance coverage rates. Selling the diabetes version separately preserves that coverage path.
- Pricing leverage: Eli Lilly can adjust pricing for each brand independently based on specific market dynamics (formulary negotiations, employer benefit programs, etc.).
Cash-Pay Reality: Why Both Cost ~$1,000+/Month
Without insurance, both Mounjaro and Zepbound cost approximately $1,000–$1,200/month at retail pharmacies in 2026. Eli Lilly offers savings cards that can reduce out-of-pocket cost in some scenarios:
- Mounjaro Savings Card: May reduce cost to as low as $25/month for eligible commercially insured patients with a diabetes diagnosis. Strict eligibility — most cash-pay patients don't qualify.
- Zepbound Savings Card: Available for commercially insured patients without coverage; approximately $650/month for eligible self-pay patients in some scenarios. Eligibility caps and program changes apply.
- LillyDirect: Eli Lilly's direct-to-patient program offers Zepbound at approximately $500–$549/month for self-pay patients — not the same as standard pharmacy pricing.
For most patients without insurance who don't qualify for the savings cards, Mounjaro and Zepbound are economically prohibitive at $12,000–$14,400/year.
The Compounded Tirzepatide Alternative
During the FDA's 2023–2024 declaration of tirzepatide as in shortage, licensed compounding pharmacies were authorized to produce tirzepatide for patient prescriptions. Many telehealth providers continue to offer compounded tirzepatide under the FDA 503A pathway, with prices dramatically below brand-name cash pricing.
Luma Health's compounded tirzepatide at $165/month is one of the lowest legitimate options nationally:
- Same active ingredient (tirzepatide) as Mounjaro and Zepbound
- Sourced from VialsRX, a licensed 503A compounding pharmacy
- $165/month flat, no membership fee, no shipping fee
- 5–10 minute online intake; provider review same-day to 24–48 hours; medication ships in 2–3 business days
- Annual cost: $1,980 vs. $12,000–$14,400 for brand-name retail
Cost Difference: Compounded vs. Brand-Name Retail
When to Choose Mounjaro
- You have type 2 diabetes — Mounjaro is FDA-approved for this, and insurance coverage is more likely
- Your insurance covers Mounjaro and the copay is reasonable
- You qualify for the Mounjaro Savings Card and the discounted price beats compounded options
- You specifically want the Eli Lilly-manufactured brand-name product
When to Choose Zepbound
- You're using tirzepatide specifically for weight loss (not diabetes)
- Your employer's insurance plan includes weight loss medication coverage
- You qualify for the Zepbound Savings Card and the price is comparable to alternatives
- LillyDirect's $500–$549/month self-pay option fits your budget
When to Choose Compounded Tirzepatide
- You're paying cash and don't have insurance coverage for either brand
- Cost is a meaningful factor — $1,980/year vs. $12,000+/year is a substantial difference
- You don't qualify for Eli Lilly's savings cards or LillyDirect
- You prefer telehealth convenience (no in-person pharmacy pickup required)
- You're comfortable with the FDA 503A compounding pathway as a legitimate medical option
About tirzepatide: Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist, FDA-approved as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. In the SURMOUNT-1 Phase 3 trial, the active ingredient produced an average 20.9% body-weight reduction at the 15mg dose at 72 weeks — among the highest weight-loss outcomes of any FDA-approved obesity medication studied to date.
Source: Jastreboff et al., New England Journal of Medicine, 2022 (SURMOUNT-1)
Frequently Asked Questions
Yes. Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg). Both are made by Eli Lilly. The only difference is FDA approval pathway: Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management.
Regulatory and commercial reasons. The FDA approves drugs for specific indications, and pharmaceutical companies typically launch a brand name for each indication. Mounjaro launched first (May 2022, for diabetes); Zepbound launched second (November 2023, for weight loss). Same molecule, two FDA labels, two prescription paths.
Cash price is similar — both run approximately $1,000–$1,200/month without insurance in 2026. With insurance, Mounjaro is more often covered, because diabetes coverage is more standard than weight loss coverage. Zepbound coverage is less common but expanding as more employers add anti-obesity medication benefits.
Yes — your provider can switch your prescription. Same molecule, same dose, same effect; only the label changes. Some patients switch because their insurance covers one but not the other. Your weight loss results, side effects, and titration schedule remain identical regardless of which brand name is on the box.
Compounded tirzepatide is significantly cheaper than either brand-name option. Luma Health offers compounded tirzepatide at $165/month flat — roughly 1/7th the cost of cash-pay Mounjaro or Zepbound. The medication is the same active ingredient (tirzepatide); the difference is FDA-approved brand vs. FDA 503A-pathway compounded version.
The active ingredient is identical, so effectiveness should be comparable for most patients. Brand-name versions have the advantage of pharmacokinetic studies and uniform Eli Lilly manufacturing. Compounded versions from licensed 503A pharmacies like VialsRX use the same active ingredient with rigorous quality controls. For cost-sensitive patients, compounded tirzepatide offers similar weight loss outcomes at a fraction of the price.
Generally no. Mounjaro is FDA-approved for type 2 diabetes, so insurance typically only covers it for that diagnosis. If you have diabetes AND want weight loss benefit, your doctor may prescribe Mounjaro and insurance may cover it. For weight loss alone without a diabetes diagnosis, Zepbound is the FDA-approved option, and insurance coverage varies significantly by employer plan.